Frontiers of Medical Technology: Reflections on the Intersection of Innovation and the Health Care System by Foote, Susan B.
Minnesota Journal of Law, Science & Technology 
Volume 7 Issue 1 Article 7 
2005 
Frontiers of Medical Technology: Reflections on the Intersection 
of Innovation and the Health Care System 
Susan B. Foote 
Follow this and additional works at: https://scholarship.law.umn.edu/mjlst 
Recommended Citation 
Susan B. Foote, Frontiers of Medical Technology: Reflections on the Intersection of Innovation and the 
Health Care System, 7 MINN. J.L. SCI. & TECH. 79 (2005). 
Available at: https://scholarship.law.umn.edu/mjlst/vol7/iss1/7 
The Minnesota Journal of Law, Science & Technology is published by the 
University of Minnesota Libraries Publishing. 




Frontiers of Medical Technology:  Reflections on 
the Intersection of Innovation and the Health Care 
System 
Susan Bartlett Foote* 
In Professor Chen’s provocative introductory essay to this 
issue, he notes that C.P. Snow’s observations in his famous 
lecture, The Two Cultures, still resonate in our society.1  Snow 
condemned the dominant literary culture’s failure to embrace 
science and the consequences to the “underfed . . . [who] die 
before their time.”2  Snow yearned for a bridge over the divide, 
“something like a third culture,” comprising a community of 
social scientists “concerned with how human beings are living 
or have lived.”3 
Recognizing the need for social science to build bridges, 
University of Minnesota’s conference4 sought to address the 
intersection between the “life sciences and the political 
demands and social aspirations of the law.”5  My specific 
challenge was to explore the interface between innovation in 
medical technology and the political and social demands of the 
health care delivery system.  This interface is constantly 
evolving in response to technological innovation. 
C.P. Snow and his generation would be surprised by the 
                                                          
      ©     2005 Susan Bartlett Foote.       
       *    J.D., M.A.  Associate Professor, Division of Health Services Research 
and Policy, University of Minnesota School of Public Health. 
 1. Jim Chen, The Midas Touch, 7 MINN. J.L. SCI. & TECH., at i (2005) 
(citing C.P. SNOW, THE TWO CULTURES: AND A SECOND LOOK 22 (2d ed. 
1964)). 
 2. SNOW, supra note 1, at 6-7. 
 3. Id. at 70. 
 4. “Where are Law, Ethics and the Life Sciences Headed?  Frontier 
Issues,” cosponsored by the University of Minnesota’s Consortium on Law and 
Values in Health, Environment & the Life Sciences and Joint Degree Program 
in Law, Health and the Life Sciences and the Minnesota Journal of Law, 
Science & Technology (May 20, 2005). 
 5. Chen, supra note 1, at iii. 
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rapid acceleration of advances in medical technology and its 
enthusiastic embrace by Americans.  From the perspective of 
the 1950s, when Snow penned his controversial lecture,6 we 
have taken an audacious leap.  Medical technology harnesses 
scientific and engineering advances, born out of the industrial 
revolution and transformed in the late twentieth century, to 
alter, replace, and repair a dizzying array of human functions.7  
The success of technology in extending life and improving the 
quality of life is reflected in the importance that Americans 
place on access to health care.  After all, we spent $1.7 trillion 
or $5,670 per capita (15.3% of GDP), in 2003 on health.8  
Indeed, just as science held the potential to ameliorate “the 
underfed” of Snow’s day, so now does access to medical care, in 
all of its technological splendor, distinguish between those who 
have and those who have not. 
It is essential to note that medical technology does not 
enter American society unencumbered.  Our embrace is not 
unconditional; it is, in fact, quite fickle.  Law conditions 
medical technology’s arrival by imposing high social standards 
of safety.  Once a technology is approved for marketing, the 
health care delivery system imposes further constraints. 
Before embarking on an exploration of the intersection 
between medical technology and law, we must clarify both 
terms of the equation.  What do we mean by medical 
technology?  The Office of Technology Assessment once broadly 
defined medical technology to include “drugs, devices, medical 
surgical procedures used in medical care, and the 
organizational and supportive systems within which such care 
is provided.”9  It is not surprising that innovation across such a 
wide range of activities varies significantly. 
Examples of medical technology innovation abound.  There 
have been a plethora of new drugs introduced in the last few 
decades, and the advent of biotechnology presents promise for 
conventional pharmaceuticals and combinations of drugs and 
                                                          
 6. See SNOW, supra note 1, at 1. 
 7. For a history of the evolution of medical technology, see generally 
SUSAN BARTLETT FOOTE, MANAGING THE MEDICAL ARMS RACE: PUBLIC 
POLICY AND MEDICAL DEVICE INNOVATION (1992). 
 8. See Cynthia Smith et al., Health Spending Growth Slows in 2003, 24 
HEALTH AFF. 185-86 (2005). 
 9. OFFICE OF TECH. ASSESSMENT, MEDICAL TECHNOLOGY UNDER 
PROPOSALS TO INCREASE COMPETITION IN HEALTH CARE, at ix (1982), 
available at 
http://www.blackvault.com/documents/ota/Ota_4/DATA/1982/8218.PDF. 
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biologics.10  Recent advances in molecular biology, proteomic 
technologies, cellular and tissue engineering, and genomic 
applications are just a few of the cutting-edge advances.11 
Once an insignificant part of the medical arsenal, medical 
devices are now used in thousands of interventions.12  Devices 
include implanted artificial hips and knees, a wide range of 
cardiac interventions, such as stents, pacemakers, and 
defibrillators, medical lasers, and diagnostic tools, such as 
magnetic resonance imaging, computerized tomography, and 
positron emission tomography.13  There is significant 
innovation on the horizon, including computer-assisted 
telemanipulators that merge robotics, 3-D visualization 
systems, and computer technology,14 and nanotechnology 
applications,15 to name just a few.  Medical device innovation 
embraces the frontiers of science and engineering, adapting 
computer technology, nanotechnology, and biotechnology to 
medical applications.16  Many of these technologies are 
delivered by physicians in in-patient and out-patient settings 
and are embedded in the service delivery system.17  Physicians’ 
needs and experiences in clinical settings often trigger 
innovation and incremental improvements; physicians also 
require ongoing training to effectively use innovative 
therapies.18 
A few areas of medical technology, such as reproductive 
techniques, cloning, and genetic manipulation, raise unique 
controversial ethical issues.  However, the focus here is on 
                                                          
 10. See, e.g., John Miller, Beyond Biotechnology: FDA Regulation of 
Nanomedicine, 4 COLUM. SCI. & TECH. L. REV. 1 (2003). 
 11. See generally Phil B. Fontanarosa & Catherine D. DeAngelis, Medical 
Applications of Biotechnology, 293 J. AM. MED. ASS’N 866, 866-67 (2005). 
 12. See, e.g., HEALTH INDUS. MFRS. ASS’N, OUTLOOK FOR MEDICAL 
TECHNOLOGY INNOVATION:  WILL PATIENTS GET THE CARE THEY NEED?  
REPORT 1: THE STATE OF THE INDUSTRY (2000).   
 13. See generally id. (discussing medical devices and the industry as a 
whole). 
 14. See generally Mark A. Talamini & Eric J. Hanly, Technology in the 
Operating Suite, 293 J. AM. MED. ASS’N 863, 863-66 (2005). 
 15. See Miller, supra note 10, at 5 (defining nanomedicine as “the 
monitoring, repair, construction and control of human biological systems at 
the molecular level, using engineered nanodevices and nanostructures”). 
 16. See HEALTH INDUS. MFRS. ASS’N, supra note 12, at 7-9. 
 17. See, e.g., id. at 12. 
 18. See, e.g., Cinda Becker, Shock Treatment, MODERN HEALTHCARE, May 
9, 2005, at 34, 36 (discussing advances in electrophysiology and the concurrent 
need for physician training). 
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“workaday” medical products and procedures, many in 
widespread use, that have become expected therapies for 
patients and account for billions of dollars in health care 
spending.19 
Turning to the other term in the equation, references to 
“law” in the context of health care are necessarily broad-
gauged.  The American health care system is enormously 
complex, with a mix of federal and state legislation and 
regulation by a myriad of agencies.20  It is beyond the scope of 
this paper to labor through a primer on the U.S. health care 
system.  What is important to note, however, is that medical 
device technology can be directly and indirectly affected by a 
wide range of laws and regulations and change in response to 
innovation is a frequent occurrence.21 
Each component of medical technology faces different 
regulatory and legal hurdles.  For example, the Food and Drug 
Administration’s (FDA) authority has evolved to tailor 
regulations to the specific characteristics of drugs, devices, and 
biologics.22  The FDA does not have authority to directly 
regulate physicians or the procedures that they perform; its 
scope only extends to the products that physicians use.23  Often 
change is triggered by a regulatory reaction to innovation.24  
                                                          
 19. There are controversies surrounding how the costs of medical devices 
specifically or medical technology generally are calculated to determine what 
contribution they make to health care spending.  One way is to look at the 
costs of the devices themselves, scaled to market size.  See HEALTH INDUS. 
MFRS. ASS’N, supra note 12, at 13. 
 20. See FOOTE, supra note 7, at 26-52. 
 21. See id.  
 22. Indeed, the statutory definition of medical devices describes a series of 
product types that are specifically “non-drugs,” meaning that they are not 
metabolized by the human body: 
The term “device” . . . means an instrument, apparatus, implement, 
machine, contrivance, implant, in vitro reagent, or other similar or 
related article, including any component, part, or accessory, which is 
– (1) recognized in the official National Formulary, or the United 
States Pharmacopeia, or any supplement to them, (2) intended for the 
use in the diagnosis of disease or other conditions, or in the cure, 
mitigation, treatment, or prevention of disease, in man or other 
animals, or (3) intended to affect the structure or any function of the 
body of man or other animals, and which does not achieve its primary 
intended purposes through chemical action within or on the body of 
man or other animals and which is not dependent upon being 
metabolized for the achievement of its primary intended purposes.” 
21 U.S.C. § 321(h) (2000) (emphasis added). 
 23. See FOOTE, supra note 7, at 44-45. 
 24. See Susan Bartlett Foote & Robert J. Berlin, Can Regulation Be as 
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Change can also be triggered by product failures.  Recent 
product safety scandals involving antidepressants, painkillers, 
and defibrillators have generated calls for FDA reforms.25  
Payment, coverage, insurance, and liability issues also vary for 
the components of medical technology.26  Because access to 
drugs is considered an essential part of a complete health 
regimen, increasingly there is a demand for insurance 
coverage.  The Medicare Prescription Drug, Improvement, and 
Modernization Act of 200327 designed a drug benefit for 
beneficiaries that will be implemented in 2006.28 
The common theme is constant change.  Technological 
change has dramatically affected all aspects of health care, and 
the health care system affects how that technology is 
evaluated, accepted, diffused, and reimbursed.  If 
“jurisdynamics” captures the concept of growth and change in 
law,29 medical technology exemplifies growth and change in 
health care. 
At this intersection, then, between medical technology and 
the health care system, are three “frontier policy issues”—
access to care, costs of care, and value of care.  It is to these 
that we now turn. 
ACCESS TO CARE 
The American approach to health care access is 
ambivalent.  Our government does not provide universal access 
to care, unlike nations such as Japan or Canada where all 
citizens are entitled to participate in the government-supported 
health care system.30  Access to care in America is not so 
                                                          
Innovative as Science and Technology? The FDA’s Regulation of Combination 
Products, 6 MINN. J.L. SCI. & TECH. 619, 619-39 (2005) (discussing this 
phenomenon at length). 
 25. See Gardiner Harris, F.D.A. Responds to Criticism with New Caution, 
N.Y. TIMES, Aug. 6, 2005, at A1. 
 26. See HEALTH INDUS. MFRS. ASS’N, supra note 12, at 52-62. 
     27.   Medicare Prescription Drug, Improvement, and Modernization Act of 
2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003). 
 28. For a discussion of the new prescription drug program, see Dana Gelb 
Safran et al., Prescription Drug Coverage and Seniors: Findings from a 2003 
National Survey, 24 HEALTH AFF. (WEB EXCLUSIVES) W5-152, W5-152 to W5-
166 (Supp. 1 2005), available at 
http://content.healthaffairs.org/webexclusives/index.dtl?year=2005. 
 29. See generally Jim Chen, The Pragmatic Ecologist: Environmental 
Protection as a Jurisdynamic Experience, 87 MINN. L. REV. 847 (2003). 
 30. See Strategic Pol’y & Research: Intergovernmental Affairs, Health 
Care Systems: An International Comparison 4 (2001), 
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simple.  Some Americans do receive health care as an 
entitlement.  For example, over forty million Americans qualify 
for Medicare based on age, disability, and contribution to the 
system.31  Others qualify for the Medicaid entitlement based on 
state-based criteria of low income and other welfare-related 
status indicators.32  Because the Medicaid entitlement is based 
on status, changes due to income increases, for example, can 
cause the loss of entitlement.33 
Most other Americans must ensure access, if they can, 
through private insurance.34  They purchase access either with 
employer assistance or on the open market.35  Because 
employers are not required to offer or subsidize insurance, 
many working Americans do not have employment-based 
coverage.36  Moreover, rising costs have led some employers to 
drop insurance subsidies.37  The ranks of those without any 
health insurance for at least some part of a year have swelled 
during the past ten years.38  In 2003, the number of uninsured 
Americans was forty-five million, and the uninsured population 
is predicted to grow another twenty-five percent, to fifty-six 
million Americans, by 2013.39 
These individuals are not completely without access.  
Medical technology and medical procedures are not perceived 
as run-of-the-mill consumer goods, such as computers or 
automobiles, which are available only to those with the 
resources to purchase them.  At some level, medical services 
                                                          
http://www.pnrec.org/2001papers/DaigneaultLajoie.pdf. 
 31. See http://www.medicare.gov (last visited Oct. 8, 2005). 
 32. See http://www.cms.hhs.gov (last visited Oct. 8, 2005). 
 33. See id.; see also http://www.ihs.gov (last visited Oct. 8, 2005) 
(describing access to the Indian Health Service for certain Native Americans);  
http://www.tricare.osd.mil (last visited Oct. 8, 2005) (describing access for 
active duty service personnel, through the Department of Defense program 
called Tricare); http://www.vba.va.gov (last visited Oct. 8, 2005) (describing 
access for certain veterans through the Veterans Benefits Administration). 
 34. See GARY CLAXTON, KAISER FAMILY FOUND., HOW PRIVATE 
INSURANCE WORKS: A PRIMER 1 (2002). 
 35. See id. 
 36. See KAISER FAMILY FOUND. & HEALTH RESEARCH & EDUC. TRUST, 
EMPLOYER HEALTH BENEFITS: 2005 SUMMARY OF FINDINGS 4 (2005). 
 37. See id. at 11. 
 38. See Todd Gilmer & Richard Kronick, It’s the Premiums, Stupid: 
Projections of the Uninsured Through 2013, 24 HEALTH AFF. (WEB 
EXCLUSIVES) W5-143, W5-145 ex.1 (Supp. 1 2005), available at 
http://content.healthaffairs.org/webexclusives/index.dtl?year=2005. 
 39. Id. at W5-148 to W5-149.  For an extensive discussion of the 
estimates, see generally id. 
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are treated as “merit goods” that have greater social value and 
should be more widely available.40  Therefore, hospitals are 
required by law to treat any emergencies that arrive at their 
doors, regardless of the insurance status of the patient.41  
However, these patients lack access to nonemergency needs, 
including elective, preventive, and life-saving technologies that 
are not “emergencies.” 
A recent New York Times article focused on access 
differences based not on insurance status, but based on social 
class.42  In the second in a series of articles titled Class Matters, 
the reporter traced the effect of social class, defined as “that 
elusive combination of income, education, occupation and 
wealth,” on three patients who had heart attacks in New York 
City.43  As Ichiro Kawachi, a professor of social epidemiology at 
the Harvard School of Public Health, noted in the article: “It’s 
like diffusion of innovation: whenever innovation comes along, 
the well-to-do are much quicker at adopting it. . . .  Mortality 
rates even among the poor are coming down, but the rate is not 
anywhere near as fast as for the well-to-do.”44  Bruce G. Link, a 
professor at Columbia University, observed: “We’re creating 
disparities.  It’s almost as if it’s transforming health, which 
used to be like fate, into a commodity.  Like the distribution of 
BMW’s or goat cheese.”45  Law and policy do not ensure 
equitable access to health care, especially the high-tech care 
associated with expensive drugs, devices, and life-enhancing 
procedures. 
Despite inequitable access to care, America spends more on 
health care than any other nation.46  The rising costs of health 
care threaten access for those who do not have sufficient 
resources to pay.  Technological change has played a role in 
                                                          
 40. Merit goods are defined as “those goods and services to which people 
are entitled as a birthright, simply by virtue of being members of society, 
regardless of ability to pay.”  Economic Brief No. 16: Merit Goods: A Policy 
Dilemma, COMMUNITY LEADER’S LETTER (Clemson Univ. Cmty. & Econ. Dev. 
Program, Clemson, S.C.), Summer 1994, at 2, available at 
http://www.strom.clemson.edu/teams/ced/cll/5-2Summer94.pdf. 
 41. See 42 U.S.C. § 1395dd (2000). 
 42. See Janny Scott, Life at the Top in America Isn’t Just Better, It’s 
Longer: Three Heart Attacks, and What Came Next, N.Y. TIMES, May 16, 2005, 
at A1, A14-15. 
 43. Id. at A1. 
 44. Id. at A14. 
 45. Id. 
 46. See WORLD HEALTH ORG., THE WORLD HEALTH REPORT 2004: 
CHANGING HISTORY 136–43 (2004). 
FOOTE_JCI_742.DOCINAL 01/12/2006  01:10:33 PM 
86 MINN. J.L. SCI. & TECH. [Vol. 7:1 
 
raising the cost of care.  As the noted economists David Cutler 
and Mark McClellan have found: “It is widely accepted that 
technological change has accounted for the bulk of medical care 
cost increases over time.”47  Thus, changing technology 
exacerbates access problems.   
COSTS OF CARE 
Determining how technology in medicine affects costs is a 
challenge.  When a new technology substitutes for an older 
version, the costs can either rise or fall.  At the same time, new 
technologies often lead to the expansion of the patient 
population to be treated, resulting in higher overall costs.  For 
example, when cataract surgery was improved, the number of 
surgical procedures grew.48  In 2003, the American College of 
Cardiology reported that 70,785 heart patients were eligible for 
expensive implantable cardiac defibrillators (ICDs).49  With 
expanded coverage policies for patients not quite as sick as 
traditional ICD patients, the estimate has grown to 240,000 
eligible Medicare patients in 2005.50 
Many reports praising the value of new medical 
technologies are accompanied by lamentations about their 
costs.  At the end of an article on the future of surgical robotics, 
the authors warn:  
As surgery has rushed into the world of innovation, a few cautionary 
flags are in order.  Innovative technology is very expensive. Who is 
going to pay for these advances?  Which innovations are truly better 
for patients and which are simply enticing?  Who will pay for the 
studies to distinguish between these?  Are those technology-based 
procedures that appear to be better truly cost-effective?  Are there 
sufficient safeguards in place?  Should the free market be allowed to 
decide which technologies will become entrenched, or should the 
government take a bigger role?51 
At the end of an article on ICDs, a consultant notes: “It’s 
exciting, [but] it’s just that somebody has to pay for all of 
this.”52 
                                                          
 47. David M. Cutler & Mark McClellan, Is Technological Change in 
Medicine Worth It?, 20 HEALTH AFF. 11, 11 (2001). 
 48. See IRVING SHAPIRO, MATTHEW D. SHAPIRO & DAVID W. WILCOX, 
MEASURING THE VALUE OF CATARACT SURGERY 9 (1998), available at 
http://www-personal.umich.edu/~shapiro/criw-rv2.pdf. 
 49. See Becker, supra note 18, at 34. 
 50. See id. 
 51. Talamini & Hanly, supra note 14, at 865-66. 
 52. Becker, supra note 18, at 36. 
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VALUE OF CARE 
Rising costs coupled with the rising number of uninsured 
individuals have led to calls for change.  A few have argued 
that we need to ration access to costly technologies, similar to 
efforts by Oregon to define limits for its Medicaid population.53  
Many others have called for the rationalization of utilization of 
technologies by subjecting innovations to greater scrutiny and 
by seeking to eliminate services that do not produce net 
improvements in health outcomes. 
The Medicare program has undertaken significant changes 
in its process for evaluating new technologies before making  
coverage decisions.54  Research by John Wennberg and his 
colleagues has shown significant variations in how medicine is 
practiced across the country,55 concluding that hospital and 
physician capacity is directly related to higher spending, often 
without improved quality or length of life.56  The 
Commonwealth Fund has also recently issued data 
documenting variation in quality of care in the Medicare 
program.57  Medicare is experimenting with pay-for-
performance demonstration projects,58 and physician groups 
are working to impose practice standards on their members.59 
                                                          
 53. See, e.g., Daniel M. Fox & Howard M. Leichter, Rationing Care in 
Oregon: The New Accountability, 10 HEALTH AFF. 7 (1991) (discussing 
Oregon’s rationing of its medical care resources). 
 54. For a discussion of the evolution of Medicare’s coverage process, see 
Susan Bartlett Foote, Why Medicare Cannot Promulgate a National Coverage 
Rule: A Case of Regula Mortis, 27 J. HEALTH POL. POL’Y & L. 707 (2002). 
 55. See John E. Wennberg, Practice Variations and Health Care Reform: 
Connecting the Dots, 24 HEALTH AFF. (VARIATIONS REVISITED) VAR-140, VAR-
140 to VAR-144 (2004).   
 56. See John E. Wennberg, Elliot S. Fisher & Jonathan S. Skinner, 
Geography and the Debate over Medicare Reform, 21 HEALTH AFF. (WEB 
EXCLUSIVES) W96, W98 to W102 (2002), 
http://content.healthaffairs.org/webexclusives/index.dtl?year=2002. 
 57. See SHEILA LEATHERMAN & DOUGLAS MCCARTHY, COMMONWEALTH 
FUND, QUALITY OF HEALTH CARE FOR MEDICARE BENEFICIARIES: A 
CHARTBOOK 11 (2005), available at 
http://www.cmwf.org/usr_doc/MedicareChartbk.pdf (concluding that despite 
signs of progress, there is a wide variety of quality across the country). 
 58. Press Release, Center for Medicare & Medicaid Services, Medicare 
“Pay for Performance (P4P)” Initiatives (Jan. 31, 2005), 
http://www.cms.hhs.gov/media/press/release.asp?Counter=1343. 
 59. See Warren A. Jones et al., Task Force Report 3: Report of the Task 
Force on Continuous Personal, Professional, and Practice Development in 
Family Medicine, 2 ANNALS FAM. MED. S65, S65-S74 (Supp. 2004); Doctor 
Involvement Grows in Practice-Improvement Efforts, 59 MED. & HEALTH, Apr. 
25, 2005, at 1-2. 
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These efforts in the public and private sectors are aimed at 
eliminating waste and reducing use of costly treatments whose 
marginal value is low.  That is an important goal.  However, it 
has been argued that these goals will “directly or indirectly 
retard technological progress.”60  In addition, the fragmentation 
of the American system makes comprehensive and effective 
evaluation of new technology very difficult. 
Americans have embraced the frontiers of medical 
technology.  They support investments in research and are avid 
consumers of technology.  Many of the fruits of that technology 
have resulted in longer and better lives for many Americans.  
These outcomes satisfy the call of C.P. Snow to harness science 
and technology, to alleviate need, and to show concern for “how 
human beings are living or have lived.”61  The challenge, 
however, is formidable.  Valuable medical technology must 
navigate between the Scylla of rising costs and the Charybdis 
of ensuring access to care.62  To date, our quest has been 
elusive at best as we struggle to balance social and legal values 
with science and technology in the service of improved health 
for all Americans. 
 
                                                          
 60. Cutler & McClellan, supra note 47, at 25. 
 61. SNOW, supra note 1, at 70. 
 62. See THOMAS BULFINCH, BULFINCH’S MYTHOLOGY: ILLUSTRATED 
EDITION 243-45 (1979) (recounting the story of Scylla and Charybdis, who have 
become “proverbial, to denote opposite dangers which beset one’s course”). 
